
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Miami, Fla. - Pediatric dermatologists and pediatricians often see children with purpura, which presents cutaneously but can be a sign of systemic abnormalities.






